First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study
Author:
Publisher
Elsevier BV
Subject
Pharmacology,Immunology,Immunology and Allergy
Reference34 articles.
1. Therapy for Advanced Cholangiocarcinoma: Current Knowledge and Future Potential;Wang;J Cell Mol Med,2021
2. Cholangiocarcinoma: What Are the Options in All Comers and How Has the Advent of Molecular Profiling Opened the Way to Personalised Medicine ?;Roth;Eur J Cancer,2023
3. Cholangiocarcinoma 2020: The Next Horizon in Mechanisms and Management;Banales;Nat. Rev.Gastroenterol Hepatol,2020
4. A Phase 2 and Biomarker Study of Cabozantinib in Patients with Advanced Cholangiocarcinoma;Goyal;Cancer,2017
5. Prognostic Nomogram for Intrahepatic Cholangiocarcinoma after Partial Hepatectomy;Wang;J Clin Oncol,2013
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma;International Immunopharmacology;2024-10
2. Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma;Biomedicine & Pharmacotherapy;2024-06
3. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker;Clinical and Translational Medicine;2024-06
4. The fibrosis-4 index is a prognostic factor for cholangiocarcinoma patients who received immunotherapy;Frontiers in Immunology;2024-05-10
5. Review and Application of Integrin Alpha v Beta 6 in the Diagnosis and Treatment of Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma;Technology in Cancer Research & Treatment;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3